Author: KEI Staff

WHA73: Written statement of KEI – Agenda item 3 – Address by WHO Director-General devoted to the COVID-19 pandemic response in advance of the opening of the Health Assembly

Posted on by KEI Staff

KEI is an accredited non-state actor at the World Health Organization (WHO). This is our statement at the 73rd World Health Assembly. https://extranet.who.int/nonstateactorsstatements/meetingoutline/6 Knowledge Ecology International Meeting: Seventy-third World Health Assembly Written statements on COVID-19 pandemic The biggest question today… Continue Reading →

KEI Comments Regarding NIH Exclusive License for Treatment of Cancer to NeoImmune Tech

Posted on by KEI Staff

On Friday April 17, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: The Development of Bispecific Antibodies Targeting Glypican 1 (GPC1) for the Treatment of… Continue Reading →

KEI Comments Regarding NIH Exclusive License for Adoptive Cell Therapy to Lyell Immunopharma

Posted on by KEI Staff

On Friday April 17, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Methods and Compositions for Adoptive Cell Therapy” to Lyell Immunopharma, Inc. (85 FR… Continue Reading →

KEI Letter to Speaker Pelosi Regarding Use of “Other Transaction Authority” (OTA) in Coronavirus Bill to Escape Bayh-Dole Public Interest Safeguards

Posted on by KEI Staff

For more on KEI’s work on COVID-19, see keionline.org/coronavirus. On March 23, 2020, Knowledge Ecology International (KEI) sent a letter to Speaker Nancy Pelosi regarding a provision in the current draft of the Senate version of the coronavirus funding bill… Continue Reading →

KEI Comments Regarding NIH Exclusive License to TeraImmune for T Cell Therapy

Posted on by KEI Staff

(UPDATE: The NIH provided a response to our comments on February 25, 2020) On February 3, 2020, Knowledge Ecology International (KEI) submitted comments to the “Prospective Grant of Exclusive Patent License: Development of Regulatory T-Cell Therapies for the Treatment of… Continue Reading →

KEI Comments Regarding NIH Exclusive License on Gene Therapy to Treat Ocular Disease

Posted on by KEI Staff

On Friday January 10, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Gene Therapy for Ocular Disease” to OcQuila Therapeutics, Ltd. (84 FR 65169). The… Continue Reading →